Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $26.00 price target on Inventiva SA (NASDAQ: IVA).

The analyst commented: "Takeaways From Our Well-Attended NYC Investor Dinner; We had the opportunity to host IVA for a well-attended investor dinner in NYC. Accordingly, we walked away with reinforced confidence in lanifibranor's Ph3 NATiV3 topline 4Q26 to hit stat sig on its composite primary endpoint which mitigates high placebo responses and is de-risked by the 24% placebo-adjusted improvement observed in Ph2b NATIVE. With that, recognize the bogey is for lanifibranor to recapitulate the findings of NATIVE and demonstrate an 18% placebo-adjusted improvement on ≥1-stage fibrosis without worsening of MASH. Further, note lanifibranor represents a differentiated asset as a panPPAR agonist which offers both intra- and extra- hepatic effects to drive comprehensive benefits in MASH with substantially reduced risk of fluid retention and weight gain. Ultimately, we remain bullish on IVA and believe now is the time to own ahead of this potentially major stock-moving event in 4Q26. Email us for our IVA 31 investor questions deep dive."

For an analyst ratings summary and ratings history on Inventiva SA click here. For more ratings news on Inventiva SA click here.

Shares of Inventiva SA closed at $3.86 yesterday.